Adewole M, Faniran T, Abdullah F, Ali M
Chaos Solitons Fractals. 2024; :113722.
PMID: 38620099
PMC: 10291298.
DOI: 10.1016/j.chaos.2023.113722.
Mocsar G, Volko J, Ronnlund D, Widengren J, Nagy P, Szollosi J
Biophys J. 2016; 111(1):100-12.
PMID: 27410738
PMC: 4944762.
DOI: 10.1016/j.bpj.2016.05.044.
Smith K
Front Immunol. 2012; 3:364.
PMID: 23230441
PMC: 3515962.
DOI: 10.3389/fimmu.2012.00364.
Del Blanco B, Garcia-Mariscal A, Wiest D, Hernandez-Munain C
J Immunol. 2012; 188(7):3278-93.
PMID: 22357628
PMC: 3441836.
DOI: 10.4049/jimmunol.1100271.
Shapira A, Benhar I
Toxins (Basel). 2011; 2(11):2519-83.
PMID: 22069564
PMC: 3153180.
DOI: 10.3390/toxins2112519.
Antibody-based therapy of leukaemia.
Morris J, Waldmann T
Expert Rev Mol Med. 2009; 11:e29.
PMID: 19788782
PMC: 7294739.
DOI: 10.1017/S1462399409001215.
The role of basiliximab in the evolving renal transplantation immunosuppression protocol.
Salis P, Caccamo C, Verzaro R, Gruttadauria S, Artero M
Biologics. 2009; 2(2):175-88.
PMID: 19707352
PMC: 2721359.
DOI: 10.2147/btt.s1437.
Intravenous daclizumab for recalcitrant ocular inflammatory disease.
Bhat P, Castaneda-Cervantes R, Doctor P, Foster C
Graefes Arch Clin Exp Ophthalmol. 2009; 247(5):687-92.
PMID: 19198869
DOI: 10.1007/s00417-009-1043-4.
Structural biology of shared cytokine receptors.
Wang X, Lupardus P, LaPorte S, Garcia K
Annu Rev Immunol. 2008; 27:29-60.
PMID: 18817510
PMC: 3981547.
DOI: 10.1146/annurev.immunol.24.021605.090616.
Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris J, Waldmann T, Janik J
J Immunotoxicol. 2008; 5(2):235-48.
PMID: 18569395
PMC: 7243878.
DOI: 10.1080/15476910802129661.
Soluble interleukin-2 receptors in ulcerative colitis.
Nielsen O, Brynskov J
Mediators Inflamm. 1993; 2(2):115-8.
PMID: 18475512
PMC: 2365397.
DOI: 10.1155/S096293519300016X.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann T
J Clin Immunol. 2007; 27(1):1-18.
PMID: 17216565
DOI: 10.1007/s10875-006-9060-0.
Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal.
Tamang D, Redelman D, Alves B, Vollger L, Bethley C, Hudig D
Cytokine. 2006; 36(3-4):148-59.
PMID: 17188506
PMC: 1850105.
DOI: 10.1016/j.cyto.2006.11.008.
Cytoplasmic targeting motifs control localization of toll-like receptor 9.
Leifer C, Brooks J, Hoelzer K, Lopez J, Kennedy M, Mazzoni A
J Biol Chem. 2006; 281(46):35585-92.
PMID: 16990271
PMC: 2758030.
DOI: 10.1074/jbc.M607511200.
Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus infection.
Murray P, Oates J, Reynolds G, Crocker J, Young L
Clin Mol Pathol. 1995; 48(2):M105-8.
PMID: 16695980
PMC: 407934.
DOI: 10.1136/mp.48.2.m105.
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman C, Ravetch J
Blood. 2006; 108(2):705-10.
PMID: 16551968
PMC: 1895489.
DOI: 10.1182/blood-2005-11-4607.
A carbohydrate neoepitope that is up-regulated on human mononuclear leucocytes by neuraminidase treatment or by cellular activation.
Quinn M, Swain S, Parkos C, Jutila K, Siemsen D, Kurk S
Immunology. 2001; 104(2):185-97.
PMID: 11683959
PMC: 1783300.
DOI: 10.1046/j.1365-2567.2001.01300.x.
Advances in interleukin 2 receptor targeted treatment.
Morris J, Waldmann T
Ann Rheum Dis. 2000; 59 Suppl 1:i109-14.
PMID: 11053100
PMC: 1766615.
DOI: 10.1136/ard.59.suppl_1.i109.
Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.
Kobayashi H, Sun B, Han E, Kim M, Le N, Wang Q
Jpn J Cancer Res. 1998; 89(4):436-44.
PMID: 9617350
PMC: 5921826.
DOI: 10.1111/j.1349-7006.1998.tb00582.x.
Serial transplantation of adult T cell leukemia cells into severe combined immunodeficient mice.
Imada K, Takaori-Kondo A, Sawada H, Imura A, Kawamata S, Okuma M
Jpn J Cancer Res. 1996; 87(9):887-92.
PMID: 8878449
PMC: 5921197.
DOI: 10.1111/j.1349-7006.1996.tb02116.x.
